The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Teva Pharmaceutical Industries Ltd  (TEVA) Trade Now »     Rate TEVA  -  Discuss TEVA  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
78.5%
Top:
75.0%
Rate TEVA:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

TEVA: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

New Stock Indexes to Track Trends in Healthcare Sector Graphic_rating_buy TEVA
Mikerun
73%

Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. 

<> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index

The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with <><><><><><><><><><><><><><><><><><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><><><><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< /><><><><><><><><><>...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/28/09 Comment


FDA, Clinical Trial Calendar Updates: THRX, GILD, TEVA, ALNY, RNUGF Graphic_rating_buy TEVA
Mikerun
73%
Below is a summary of updates to the BioMedReports.com database of 239 entries included in the FDA and Clinical Trial Calendars .
 
 The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description.  
 
<> The Clinical Trial Calen...
By  Mike Havrilla   (+1.04%  risk: conservative)  04/06/09 Comment


Momenta Pharma's Three-Part Strategy Graphic_rating_buy TEVA
Mikerun
73%
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB).
 
<> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awarded to the first-to-file company is set to expire on 4/1/09 for Amphasta...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/06/09 Comment


Big Pharma Goes Generic Graphic_rating_buy TEVA
Mikerun
73%
Big Pharma Goes Generic edit
<> <> <> <> <> <> Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/26/09 Comment


Caraco Pharma Awaits FDA Inspection in May Graphic_rating_buy TEVA
Mikerun
73%
By Mike Havrilla on 2/25/09
 
I spoke with the investor relations representative for Caraco Pharma (CPD) earlier this week and received some clarity on the expected timeline for resolving the major overhang on the stock price related to the FDA warning letter over Form 483 concerns by the agency stemming from quality control issues raised during an inspection of manufacturing facilities last year.
 
<> Caraco has responded in full to the warning letter and the FDA will evaluate the corrective actions taken by the Company at its next s...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/25/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
T AT&T Inc
MA MasterCard Inc
MSFT Microsoft Corp
SBUX Starbucks Corp
INTC Intel Corp
AAPL Apple Computer Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on TEVA

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Teva Pharmaceutical Industries Ltd - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch